In Vitro Antiviral Activity of Tyrosinase from Mushroom Agaricus bisporus against Hepatitis C Virus
Open Access
- 3 August 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceuticals
- Vol. 14 (8) , 759
Abstract
Tyrosinases from a commercial Agaricus bisporus protein extract and directly isolated from white mushrooms were purified in order to obtaining the well-known tyrosinase from A. bisporus (TyrAB) of 45 kDa and a newly discovered 50 kDa tyrosinase isoform (Tyr50 kDa), and tested showing high antiviral activity against the hepatitis C virus for the first time. Cell toxicity and antiviral activity of tyrosinases were determined in cultured Huh 5-2 liver tumor cells transfected with a replicon system (a plasmid that includes all non-structural hepatitis C virus proteins and replicates autonomously). TyrAB was able to inhibit the replication of the hepatitis C virus without inducing toxicity in liver cells. In addition, the post-translational isoform Tyr50 kDa showed higher antiviral capacity than the former (up to 10 times greater), also exhibiting 10 times higher activity than the commercial drug Ribavirin®. This antiviral activity was directly proportional to the enzymatic activity of tyrosinases, as no antiviral capacity was observed in the inactive form of the enzymes. The tyrosinases approach could represent a new antiviral inhibition mechanism, through a plausible catalytic mechanism of selective hydroxylation of the key role of tyrosine residues in viral proteases.Keywords
This publication has 30 references indexed in Scilit:
- Allosteric Inhibitors of the NS3 Protease from the Hepatitis C VirusPLOS ONE, 2013
- Current and Future Therapies for Hepatitis C Virus InfectionNew England Journal of Medicine, 2013
- Hepatitis C Virus RNA Translation2013
- Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral TargetJournal of Biological Chemistry, 2010
- The NS4A Protein of Hepatitis C Virus Promotes RNA-Coupled ATP Hydrolysis by the NS3 HelicaseJournal of Virology, 2009
- Hepatitis C virus NS2 is a protease stimulated by cofactor domains in NS3Proceedings of the National Academy of Sciences, 2009
- Hepatitis C virus therapiesNature Reviews Drug Discovery, 2006
- Modelling how ribavirin improves interferon response rates in hepatitis C virus infectionNature, 2004
- Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell LineScience, 1999
- The role of tyrosinase in autoimmune vitiligoThe Lancet, 1994